Updated on 23 January 2013
The greatest value increase is expected from the sickle cell anemia market
Singapore: According to GBI Research, global therapeutic markets for sickle cell anemia, thalassemia and hereditary angioedema (HAE) are all expected to exhibit uninspired growth. The greatest value increase is expected from the sickle cell anemia market, which is forecast to climb at a Compound Annual Growth Rate (CAGR) of nine percent, from $36m in 2012 to $70m in 2019.
Meanwhile, the global HAE therapeutics market is predicted to increase at a CAGR of three percent during the same period, from $1.5 billion to $1.9 billion.
Mr Kimberley Carter, Associate Analyst at GBI Research said, "Even though orphan blood disorders are rare, the three diseases featured in this report are hereditary and have a large impact on the lives of the families and ethnic groups afflicted by these diseases. Many of these diseases cause debilitating health issues and limit lifespan. Because of this there is a great need for curative and disease modifying therapies."
"While this may require significant R&D investment, any drugs that are successful in treating these diseases can be expected to be priced at the highest premium range."
All three ailments studied in the new report have weak product pipelines, with most upcoming treatments either too similar to currently available options, or insufficiently promising to make any real impact.